Abstracts Archive - Page 473 of 2425 - ACR Meeting Abstracts

Abstract Number: 2069 • ACR Convergence 2022
Responsiveness of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort
Aarabi Thayaparan¹, Patricia Katz², Mitra Moazzami³, Dennisse Bonilla¹, Lisa Engel⁴, Jiandong Su¹, Pooneh Akhavan⁵, Sherief Marzouk⁶, Nathalie Rozenbojm⁷, Nicole Anderson¹, Oshrat Tayer-Shifman⁸, Dorcas Beaton⁹ and Zahi Touma¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²UCSF, San Rafael, CA, ³George Washington University, Washington, DC, ⁴University of Manitoba, Winnipeg, MB, Canada, ⁵Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶University Health Network, University of Toronto, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada, ⁸Meir Medical Center, Kfar Saba, Israel, ⁹Institute for Work & Health, Toronto, ON, Canada
Background/Purpose: Clinicians should include Patient-Reported Outcome (PRO) measures in the assessment of lupus patients, as they are crucial in providing patient-centred care. The Patient Reported…
Abstract Number: 2036 • ACR Convergence 2022
Development of Systemic Sclerosis in Patients with Primary Sjogren Syndrome and Raynauds Phenomenon
Andres Martinez¹, Julieta Morbiducci¹, Constanza Arguissain¹, Maria Tamborenea¹, Marisel Bejarano², Lucia Castorino¹ and Anastasia Secco¹, ¹Rivadavia Hospital, Buenos Aires, Argentina, ²Rivadavia´s Hospital, Buenos Aires, Argentina
Background/Purpose: Primary Sjögren's Syndrome (pSS) is an autoimmune disease, and Raynaud's Phenomenon (RP) is an extraglandular manifestation that can evolve into a systemic sclerosis-overlap syndrome.…
Abstract Number: 2088 • ACR Convergence 2022
Achieving Systemic Lupus Erythematosus Disease Control or Low Lupus Disease Activity State Is Associated with Lower Rates of Organ Damage: Results from the Hopkins Lupus Cohort
Jacob N. Hunnicutt¹, Mary E. Georgiou², Anna Richards², Holly Quasny³, Laurence S Magder⁴, Daniel W. Goldman⁵ and Michelle Petri⁵, ¹GlaxoSmithKline, Value Evidence and Outcomes, Collegeville, PA, ²GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom, ³GlaxoSmithKline, Clinical Sciences, Research Triangle Park, NC, ⁴University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ⁵Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: The treatment target for systemic lupus erythematosus (SLE) is remission or, if this cannot be reached, the lowest disease activity achievable with the least…
Abstract Number: 2090 • ACR Convergence 2022
Evaluation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) vs. SLEDAI-2K Glucocorticoids (SLEDAI-2KG) on Patient Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE)
Alan Cheng¹, Vibeke Strand², Jiandong Su³, Nicole Anderson³, Lee S Simon⁴ and Zahi Touma³, ¹Michael G. DeGroote School of Medicine, McMaster University, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ²Stanford University School of Medicine, Stanford, CA, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁴SDG LLC, West Newton, MA
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Glucocorticoid Index (SLEDAI-2KG) is a novel valid index able to measure disease activity while accounting for prednisone…
Abstract Number: 2075 • ACR Convergence 2022
Risk of Bloodstream Infection in Patients with Systemic Lupus Erythematosus Exposed to Prolonged Moderate to High Dose Glucocorticoids
MI HYEON KIM¹, Eun Bong Lee¹, Eun Young Lee², Jin Kyun Park³ and Jun Won Park¹, ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul National University College of Medicine, Seoul, Republic of Korea, ³Seoul National University College of Medicine, Jongno-gu, Seoul, South Korea
Background/Purpose: This study aimed to investigate the incidence and risk factors of bloodstream infection (BSI) in patients with systemic lupus erythematosus (SLE) receiving moderate-to-high dose…
Abstract Number: 2081 • ACR Convergence 2022
COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients Following Initial Vaccination Series and Additional Dose Through the New York City Omicron BA.1 Wave
Amit Saxena¹, Alexis Engel², Brittany Banbury¹, Ghadeer Hasan³, Nicola Fraser¹, Devyn Zaminski¹, Mala Masson⁴, Rebecca Haberman⁵, Jose Scher², Gary Ho⁶, Jammie Law³, Paula Rackoff¹, Chung-E Tseng⁵, H Michael Belmont¹, Robert Clancy¹, Jill Buyon⁷ and Peter Izmirly⁷, ¹NYU School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Langone, New York, NY, ⁴NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, ⁷NYU Grossman School of Medicine, New York, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at high risk for severe disease from COVID-19 and decreased vaccine efficacy, due to inherent immune perturbations…
Abstract Number: 2087 • ACR Convergence 2022
Prospective Study of Clinical, Laboratory, and Patient-Reported Outcomes of Patients with Systemic Lupus Erythematosus Undergoing Total Hip and Total Knee Arthroplasty
David Fernandez, Insa Mannstadt, Mark Figgie, Peter Sculco, Jason Blevins, Caroline Siegel, Deanna Jannat-Khah, DrPH, MSPH, Carey Ford, Mikhail Olferiev, Dina Greenman, Kyriakos Kirou and Susan Goodman, Hospital for Special Surgery, New York, NY
Background/Purpose: Patients with SLE have doubled their utilization of THA and TKA, yet postoperative complications remain high. However, disease specific measures have not been assessed.…
Abstract Number: 2083 • ACR Convergence 2022
A Network Meta-analysis on 532 SLE Patients: Low Complement Levels in the First Trimester Predict Disease Flare in Pregnancy
Massimo Radin¹, Irene Cecchi², Francesca Crisafulli³, Evandro Mendes Klumb⁴, Guilherme Ramires De Jesús⁴, Miguel Ángel Saavedra⁵, Geraldine Vanessa Reyes-Navarro⁶, Luca iaccarino⁷, Maddalena Larosa⁷, Gabriella Moroni⁸, Francesco Tamborini⁹, dario Roccatello¹, Laura Andreoli³, Cecilia Beatrice Chighizola¹⁰ and Savino Sciascia², ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy, ³University of Brescia, Brescia, Italy, ⁴Instituto Fernandes Figueira, Rio De Janeiro, Brazil, ⁵Hospital de Especialidades Dr. Antonio Fraga Mouret, Ciudad de México, Mexico, ⁶Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, ⁷University of Padova, Padova, Italy, ⁸Humanitas University, Rozzano, Italy, ⁹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ¹⁰University of Milan, Milano, Italy
Background/Purpose: The complement system is a key-player in the pathogenesis of systemic lupus erythematosus (SLE); decrease in C3 and C4 levels correlates with disease activity…
Abstract Number: 2034 • ACR Convergence 2022
What Is the Best Initial Screening for Suspected Sjögren’s Disease?
Katja Perdan Pirkmajer, Jelka Kramarič, matija Tomšič and Alojzija Hocevar, University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: During the COVID-19 pandemic the routine diagnostic procedure in Sjögren's disease (SS) was highly hampered. The aim of our study was to determine in…
Abstract Number: 2032 • ACR Convergence 2022
Major Salivary Gland Ultrasound and Elastography for Assessment of Disease Activity in Patients of Primary Sjögren’s Syndrome
Kunal Chandwar¹, Juhi Dixit¹, Kriti Kishor¹, DOGGA PRASANNA KUMAR², DIGVIJAY EKBOTE³, PUNEET KUMAR¹ and Urmila Dhakad¹, ¹King George's Medical University, Lucknow, India, ²KGMU, LUCKNOW, Uttar Pradesh, India, ³KING GEORGE MEDICAL UNIVERSITY, LUCKNOW, Uttar Pradesh, India
Background/Purpose: To assess major salivary gland involvement by ultrasonography and elastography in patients with Sjögren's syndrome , compare it with controls and correlate the severity…
Abstract Number: 2073 • ACR Convergence 2022
The Incidence of COVID-19 Infection in an SLE Cohort, and Its Association with Immunosuppressants, SLE Disease Activity, Vaccination Status, and COVID-19 Antibodies
Laurence S Magder¹, Andrea Fava², Daniel W. Goldman³ and Michelle Petri³, ¹University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: An important clinical question is whether treatments (e.g, corticosteroids, immunosuppressants) or SLE disease activity are associated with an increased risk of COVID-19 infection among…
Abstract Number: 2035 • ACR Convergence 2022
Elucidating the Factors That Influence the Use of Minor Salivary Gland Biopsy for the Evaluation of Childhood Sjögren’s Disease
Dizon Brian¹, Matthew Basiaga², Sara Stern³, Akaluck Thatayatikom⁴, seunghee cha⁵, Scott Lieberman⁶, Hemalatha Srinivasalu⁷ and on behalf of CARRA and the childhood Sjogren's workgroup⁸, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²Mayo Clinic, Inver Grove Heights, MN, ³University of Utah, Salt Lake City, UT, ⁴AdventHealth, Orlando, FL, ⁵University of Florida, Gainesville, FL, ⁶University of Iowa, Iowa City, IA, ⁷Children's National Hospital, Washington, DC, ⁸Childhood Arthritis and Rheumatology Research Alliance, Bethesda, MD
Background/Purpose: Sjögren's disease is a rare condition in children. Diagnosis is often delayed because of the lack of pediatric-specific guidelines for childhood Sjögren's disease (cSjD).…
Abstract Number: 1785 • ACR Convergence 2022
PROs and Sociodemographic Factors in Year Prior to COVID Predict Trajectories of Depressive Symptoms in Adults with RA in First 2 Years of Pandemic: Data from the Canadian Early Arthritis Cohort
Susan Bartlett¹, orit schieir², Marie-France Valois², Janet Pope³, Louis Bessette⁴, Gilles Boire⁵, Carol Hitchon⁶, Edward Keystone⁷, Carter Thorne⁸, Diane Tin⁹, Glen Hazlewood¹⁰ and Vivian Bykerk¹¹, ¹McGill University, Montreal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³University of Western Ontario, London, ON, Canada, ⁴Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹The Arthritis Program Research Group, Newmarket, ON, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Hospital for Special Surgery, New York, NY
Background/Purpose: Growing evidence points to considerable mental health impacts of the prolonged COVID-19 pandemic, though data from longitudinal studies in rheumatic diseases are sparse. We…
Abstract Number: 1783 • ACR Convergence 2022
Exploring How and Why Organizations Identify, Adopt, Disseminate, and Sustain Evidence-based Programs for Latinos with Arthritis
Marvin Albert Meza Jarquín¹, Leigh Callahan², Serena Weisner³, Kirsten Ambrose³ and Sandra Soto⁴, ¹School of Medicine, University of North Carolina (UNC), Chapel Hill, NC, ²University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC, ³Thurston Arthritis Research Center, Chapel Hill, NC, ⁴Thurston Arthritis Research Center, UNC Division of Rheumatology, Allergy and Immunology, Chapel Hill, NC
Background/Purpose: Physical activity (PA) is effective in the self-management of arthritis. As such, several evidence-based programs aimed at supporting safe and meaningful PA have been…
Abstract Number: 2026 • ACR Convergence 2022
Serum and Tear Autoantibodies from nor Mice as Potential Diagnostic Indicators of Local and Systemic Inflammation in Sjögren’s Syndrome
Shruti Singh Kakan¹, Yaping Ju², Maria Edman² and Sarah Hamm-Alvarez³, ¹Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California; Department of Ophthalmology, Keck School of Medicine, Roski Eye Institute, University of Southern California, Los Angeles, CA, ²Department of Ophthalmology, Keck School of Medicine, Roski Eye Institute, University of Southern California, Los Angeles, CA, ³Department of Ophthalmology, Keck School of Medicine, Roski Eye Institute, University of Southern California; Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA
Background/Purpose: Sjögren's Syndrome (SS) is an autoimmune disease characterized by infiltration of lymphocytes into lacrimal (LG) and salivary (SG) glands and their concurrent loss of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].